Triasima Portfolio Management inc. Buys 1,578 Shares of Axon Enterprise, Inc $AXON

Triasima Portfolio Management inc. boosted its position in Axon Enterprise, Inc (NASDAQ:AXON) by 20.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,343 shares of the biotechnology company’s stock after acquiring an additional 1,578 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Axon Enterprise were worth $6,705,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Stone House Investment Management LLC purchased a new position in shares of Axon Enterprise in the 3rd quarter worth about $29,000. Hemington Wealth Management boosted its stake in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after buying an additional 17 shares in the last quarter. Whipplewood Advisors LLC grew its position in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 27 shares during the last quarter. Root Financial Partners LLC purchased a new position in shares of Axon Enterprise during the third quarter worth approximately $34,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Axon Enterprise in the 2nd quarter worth approximately $37,000. Institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the transaction, the chief financial officer owned 103,501 shares in the company, valued at approximately $60,030,580. This represents a 1.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of Axon Enterprise stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $600.00, for a total value of $680,400.00. Following the sale, the chief accounting officer owned 13,740 shares in the company, valued at $8,244,000. This represents a 7.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 60,540 shares of company stock worth $34,684,738. Insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

Shares of AXON stock opened at $618.86 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The firm has a market cap of $48.83 billion, a P/E ratio of 195.84, a P/E/G ratio of 20.02 and a beta of 1.41. The business’s 50 day moving average price is $572.21 and its 200-day moving average price is $680.45.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same quarter last year, the firm earned $1.45 EPS. The business’s revenue was up 30.6% on a year-over-year basis. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on AXON. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price on the stock in a research report on Tuesday, January 6th. Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Cowen restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Finally, Piper Sandler dropped their price objective on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $805.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.